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Positron emission tomography and functional characterization of a complete
PBR/TSPO knockout
Abstract
The evolutionarily conserved peripheral benzodiazepine receptor (PBR), or 18-kDa translocator protein
(TSPO), is thought to be essential for cholesterol transport and steroidogenesis, and thus life. TSPO has
been proposed as a biomarker of neuroinflammation and a new drug target in neurological diseases
ranging from Alzheimer’s disease to anxiety. Here we show that global C57BL/
6-Tspotm1GuWu(GuwiyangWurra)-knockout mice are viable with normal growth, lifespan, cholesterol
transport, blood pregnenolone concentration, protoporphyrin IX metabolism, fertility and behaviour.
However, while the activation of microglia after neuronal injury appears to be unimpaired, microglia from
GuwiyangWurraTSPO knockouts produce significantly less ATP, suggesting reduced metabolic activity.
Using the isoquinoline PK11195, the ligand originally used for the pharmacological and structural
characterization of the PBR/TSPO, and the imidazopyridines CLINDE and PBR111, we demonstrate the
utility of GuwiyangWurraTSPO knockouts to provide robust data on drug specificity and selectivity, both in
vitro and in vivo, as well as the mechanism of action of putative TSPO-targeting drugs.
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Positron emission tomography and functional
characterization of a complete PBR/TSPO knockout
Richard B. Banati1,2,3,4, Ryan J. Middleton1, Ronald Chan2,3, Claire R. Hatty2,3, Winnie Wai-Ying Kam1,2,3,
Candice Quin2,3, Manuel B. Graeber2,3,5, Arvind Parmar1, David Zahra1, Paul Callaghan1, Sandra Fok2,
Nicholas R. Howell1, Marie Gregoire1, Alexander Szabo1,6, Tien Pham1, Emma Davis1 & Guo-Jun Liu1,2,3

The evolutionarily conserved peripheral benzodiazepine receptor (PBR), or 18-kDa translocator protein (TSPO), is thought to be essential for cholesterol transport and
steroidogenesis, and thus life. TSPO has been proposed as a biomarker of neuroinﬂammation
and a new drug target in neurological diseases ranging from Alzheimer’s disease to anxiety.
Here we show that global C57BL/6-Tspotm1GuWu(GuwiyangWurra)-knockout mice are viable with
normal growth, lifespan, cholesterol transport, blood pregnenolone concentration, protoporphyrin IX metabolism, fertility and behaviour. However, while the activation of microglia
after neuronal injury appears to be unimpaired, microglia from GuwiyangWurraTSPO knockouts
produce signiﬁcantly less ATP, suggesting reduced metabolic activity. Using the isoquinoline
PK11195, the ligand originally used for the pharmacological and structural characterization of
the PBR/TSPO, and the imidazopyridines CLINDE and PBR111, we demonstrate the utility of
GuwiyangWurraTSPO knockouts to provide robust data on drug speciﬁcity and selectivity, both
in vitro and in vivo, as well as the mechanism of action of putative TSPO-targeting drugs.

1 Life Sciences, Australian Nuclear Science and Technology Organisation, Locked Bag 2001, Kirrawee DC, New South Wales 2232, Australia. 2 Brain & Mind
Research Institute, The University of Sydney, Sydney, New South Wales 2006, Australia. 3 Medical Imaging & Radiation Sciences, Faculty of Health Science
and Brain & Mind Research Institute, The University of Sydney, Sydney, New South Wales 2006, Australia. 4 National Imaging Facility, Sydney, Camperdown,
New South Wales 2006, Australia. 5 Sydney Medical School, The University of Sydney, Sydney, New South Wales 2006, Australia. 6 Centre for Translational
Neuroscience, University of Wollongong, Wollongong, New South Wales 2522, Australia. Correspondence and requests for materials should be addressed to
R.B.B. (email: rib@ansto.gov.au or Richard.Banati@sydney.edu.au) or to G.-J.L. (email: gdl@ansto.gov.au).

NATURE COMMUNICATIONS | 5:5452 | DOI: 10.1038/ncomms6452 | www.nature.com/naturecommunications

& 2014 Macmillan Publishers Limited. All rights reserved.

1

ARTICLE

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6452

complex4,7. However, recent observations that a conditional
knockout in testicular Leydig cells appeared not to affect
hormone production8 have controversially been interpreted as
evidence that the PBR/TSPO, unlike the steroidogenic acute
regulatory protein (StAR)9,10, is not an essential requirement for
steroid hormone biosynthesis11,12. No further data indicating
other potential impairments have been reported.
An important observation that has underpinned the growing
interest related to the PBR/TSPO is the regularly seen increase of
the PBR/TSPO in areas of brain injury and during ‘neuroinﬂammation’, most prominently in activated microglia1,13,14.
Our study provides a ﬁrst extensive reference description of the
constitutive phenotype of a global Tspo knockout animal model
in vitro and in vivo. It addresses some of the fundamental
questions, in regard to the long-term viability of animals without
any potentially compensating PBR/TSPO-expressing cells,

A

ccording to current concepts, the most important
function of the mitochondrial membrane protein peripheral benzodiazepine receptor (PBR)/18-kDa translocator
protein (TSPO) is the regulation of steroid hormone production
by helping to translocate cholesterol, the precursor to pregnenolone, across the aqueous mitochondrial intermembrane space, a
view emphasized by the recent renaming of the PBR as
translocator protein (TSPO)1,2. A large body of literature2–4 on
the regulatory inﬂuence of the PBR/TSPO on steroid-mediated
homeostasis, including the reported embryonic lethal effects of a
Tspo knockout5, has established the PBR/TSPO as essential for
life. Its critical role as an endocrine regulator is the prevailing
explanation for the observed actions of PBR/TSPO binding drugs
across an exceptionally broad therapeutic spectrum from the antiinﬂammatory treatment of Alzheimer’s disease6 to anxiolysis
without direct effects on the central GABAA receptor protein

a

P1

P2

1

Wild-type Tspo
allele

Probe

P3

2

3

4

loxP site
2

Targeting
construct

3

2

1

Targeted Tspo
allele

3

M

4
neoR

1

Tspo knockout
allele

b

4
neoR

c

+/+ +/– +/– –/– +/–

4

M

+/+

+/–

–/–

NTC Positive

8.8 kb

489 bp
246 bp

4.2 kb

60
50

49.9

40
30

19.1
15.1

20

13.2
10.0 8.2 7.3
6.5 5.8
4.3 3.7
1.8 1.0

10
0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

Ad
re
n
Lu al
M ng
ar
Ki row
d
Sp ney
le
e
L n
Bl ive
ad r
de
Pa He r
nc art
re
a
Ey s
M es
us
c
Bo le
n
Br e
ai
n
Ad
re
n
L al
M un
ar g
Ki row
d
Sp ney
le
e
L n
Bl ive
ad r
de
Pa He r
nc ar
re t
a
Ey s
M es
us
c
Bo le
n
Br e
ai
n

Normalized Tspo mRNA
expression

d

Tspo+/+

e

Tspo–/–

Kidney
M

+/+

+/–

Spleen
–/–

+/+

+/–

Testis
–/–

+/+

+/–

–/–

20 kDa

TSPO

40 kDa

GAPDH

30 kDa

Figure 1 | Generation and conﬁrmation of global Tspo  /  mice. (a) The Tspo gene was knocked out using a targeting construct with loxP sites ﬂanking
exons 2 and 3 (also see Supplementary Fig. 1). (b,c) Southern blot analysis (b) and PCR (BV2 mouse microglia were used as the positive control)
(c) demonstrated the correct targeting of the Tspo gene. (d,e) Tspo mRNA expression across 13 tissues (triplicates, mean and standard deviation;
normalized to Gapdh and Actb) (d) and measurement of TSPO protein by western blot of lysates from the kidney, spleen and testis (e) conﬁrmed
the complete absence of any Tspo gene product in Tspo  /  mice.
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whether they have altered steroid levels or any other loss of
function and whether speciﬁcity and selectivity can be assumed
for some of the most widely used PBR/TSPO-ligands.
Results
Conﬁrmation of global Tspo þ /  and Tspo  /  knockout.
Removal of exons 2 and 3 of the Tspo gene resulted in viable
Tspo þ /  and Tspo  /  animals. Following the removal of exons
2 and 3 only exons 1 and 4 remain, both of which do not contain
any start codons in the TSPO reading frame. Therefore, no TSPO
protein, or truncated TSPO protein can be produced (Fig. 1a).

A more detailed illustration of how the loss of exons 2 and 3 and
subsequent merger of exon 1 and exon 4 cannot give rise to any
functional fragment of the PBR/TSPO but possibly only an
unrelated protein with no sequence similarity is shown in
Supplementary Fig. 1.
The targeted deletion of Tspo and complete loss of TSPO
protein was conﬁrmed by Southern blot, PCR, RT-PCR,
RT-qPCR, Western blot, (Fig. 1b–e and Supplementary Fig. 1),
speciﬁc antibody staining against amino acids 156–169 at the
C-terminus of the PBR/TSPO in tissues and macrophages from
Tspo þ / þ , Tspo þ /  and Tspo  /  mice (Fig. 2), in vivo tracer
kinetic PET/CT studies using the PBR/TSPO ligand [18F]PBR111
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Figure 2 | Conﬁrmation of global Tspo knockout mice with immunostaining. (a) Anti-TSPO antibody staining showed the presence of TSPO (here shown
in the kidney and testis) in the wild-type and absence in the knockout Tspo  /  mice. The slides were the same as previously used for autoradiography with
the selective TSPO-binding ligand [3H]PK11195 (Fig. 4). (b) Antibody staining of Tspo þ / þ and Tspo þ /  macrophages validates mitochondria as the
primary site of the TSPO, which is entirely absent in Tspo  /  mice. No obvious difference in intracellular density or distribution of the mitochondria was
detected in the Tspo  /  mice (green ¼ TSPO; red ¼ mitochondria; yellow ¼ merged image; blue ¼ nucleus; scale bars: (a) 500 mm and (b) 20 mm).
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Figure 3 | No constitutive TSPO ligand binding in Tspo  /  mice. (a) Tspo þ / þ , Tspo þ /  and Tspo  /  mice are identical in external appearance and
general behaviour. However, in vivo imaging (8 males of the same age for each genotype) with PET/CT using the radioligand [18F]PBR111, the 18F-labelled
analogue to [125I]CLINDE, strikingly illustrates that (apart from occasional signals originating from the excretory pathways, such as gut and urinary bladder)
Tspo  /  mice show no ligand binding (thus also demonstrating the selectivity of the used ligand), while both Tspo þ / þ and Tspo þ /  mice have the
characteristic distribution of ligand binding, that is, in organs with known high TSPO expression, notably kidney and adrenal gland (green circle). The
images are displayed with the colour scaling and are directly comparable (highest values are white). The time-point frame of the PET images is 15–20 min
after injection and scaling is 3.8–17.9% ID per cm3. (b) The kinetics of [18F]PBR111, and the displacement of the radioligand after injection (indicated
by arrows) with cold PBR111 (1 mM) to establish non-speciﬁc binding, demonstrates that Tspo  /  mice do not have speciﬁc binding of [18F]PBR111 in
any organs, while the ligand kinetic in Tspo þ / þ and Tspo þ /  mice indicates speciﬁc binding (ID ¼ injected dose; n ¼ 4 for each genotype; error bars
denote standard deviation).

(Fig. 3), receptor-autoradiography and membrane receptor
binding (Figs 4 and 5) using [3H]PK11195 (Fig. 6a) and
[125I]CLINDE (Fig. 6b).
In addition, PBR/TSPO receptor membrane-binding data as
well as extensive receptor autoradiographic validation for all
major organs and the whole body of neonatal mice in all three
genotypes conﬁrm the absence of the PBR/TSPO protein in
the Tspo  /  mice and the high selectivity of [3H]PK11195 in
tissues where the PBR/TSPO is present (Fig. 4a,c,e,g,h and
Supplementary Fig. 2). Further, we demonstrate in vivo and
in vitro the high selectivity of [18F]PBR111 and [125I]CLINDE
(Figs 3,4b,d,f and 5), which are thus the ﬁrst new compounds for
the PBR/TSPO validated in animals with a null background of
any constitutive, or lesion-induced, speciﬁc TSPO binding.
Importantly, we show that in Tspo  /  animals, unlike in the
normal wild-type, the microglial cell response in the facial
nucleus after peripheral facial nerve lesion is not associated with
an increase in the binding of the PBR/TSPO ligands,
[3H]PK11195 and [125I]CLINDE. This demonstrates that in
pathologic tissue changes the selectivity of [3H]PK11195 and
[125I]CLINDE holds true and no additional non-selective binding
emerges (Fig. 6a–e). Our data also indicate that the early stage of
perineuronal microglial activation, with its typical change in
4

microglial morphology, is not noticeably inﬂuenced by the loss of
the PBR/TSPO and that the neuro-glial signaling mechanism
remains intact (Fig. 6f,g).
We further demonstrate the background-free detection of
syngeneic PBR/TSPO-expressing glioma cells growing in the
brains of Tspo  /  animals in vitro and in vivo using the selective
PBR/TSPO ligands, [3H]PK11195 and [18F]PBR111, as well as
antibody staining against the PBR/TSPO. This approach tests
simultaneously for the absence (respectively presence) of several
recognition or binding domains that make up the full PBR/TSPO,
whereby the PBR/TSPO-expressing tumour serves as an internal
positive control within the same animal. As predicted from the
readable sequences remaining after the deletion of exons 2 and 3,
the tissue of Tspo  /  animals cannot express any functional
domains of the PBR/TSPO or similar proteins, whereas the
Tspo þ / þ tumours express the protein as expected (Fig. 7 and
Supplementary Fig. 3).
General health and behavioural phenotyping. The observation
of over 600 animals did not reveal any overt clinical impairment
under standard diet (Supplementary Table 1) and normal housing
conditions, nor increase in incidental pathologies in either
heterozygous Tspo þ /  or homozygous Tspo  /  animals, both
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Figure 4 | Comparative receptor autoradiography and membrane binding. (a–f) The receptor autoradiographs (16 mm sections) show total binding of
[3H]PK11195 (1 nM) and [125I]CLINDE (3 nM) as well as competitive binding with 10 mM unlabelled CLINDE (CB(CL)), PK11195 (CB(PK)) and PBR111
(CB(PBR)) in the spleens (a,b), kidneys (c,d) and testes (e,f) of Tspo þ / þ , Tspo þ /  and Tspo  /  mice. Speciﬁc binding of 3 nM [125I]CLINDE and
1 nM [3H]PK11195 is clearly visible in tissue sections from Tspo þ / þ and Tspo þ /  mice and is displaceable by the unlabelled ligands. There is no speciﬁc
binding in Tspo  /  tissue. (g,h) Speciﬁc binding using [3H]PK11195 in testicular tissue (g) and kidney tissue (h) (n ¼ 3 for each genotype Tspo þ / þ ,
Tspo þ /  and Tspo  /  ). Tspo þ /  mice (kidney (Bmax and Kd): 45,361.0 fmol per mg and 5.94 nM; testes: 3,696.0 fmol per mg and 7.32 nM) have
approximately half the binding of Tspo þ / þ mice (kidney: 108,934.0 fmol per mg and 12.90 nM; testes: 4,920.0 fmol per mg and 2.66 nM) while
Tspo  /  mice have no appreciable binding. Curves represent non-linear regression of experimentally obtained data points and data are expressed
as percentage relative to Tspo þ / þ speciﬁc binding. Error bars denote standard deviation.
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phenotype in both sexes remained largely unaffected by the
heterozygous or homozygous loss of the Tspo gene, the only
exception being a statistically signiﬁcant trend increase in natural
killer (NK) cells in female Tspo  /  mice compared to female
Tspo þ / þ (Supplementary Table 3). Thus, the Tspo  /  mice did
not reveal the changes in cellular blood composition seen in
zebraﬁsh tspo gene silencing experiments15.
The concentrations of protoporphyrin IX (PPIX), thought to
be an endogenous PBR/TSPO ligand, in the blood of Tspo þ / þ ,
Tspo þ /  and Tspo  /  mice were indistinguishable and
increased similarly after treatment with 5-aminolevulinic acid
(ALA), the ﬁrst intermediate in haem biosynthesis and a
precursor of PPIX (Fig. 8d), thus indicating normal haem
metabolism.

Tspo–/–

Figure 5 | Whole-body receptor autoradiography of neonatal mice.
Receptor autoradiography using the TSPO ligand [125I]CLINDE on whole
bodies of 2-day-old neonatal mice. The autoradiographs show total binding
of [125I]CLINDE (3 nM) as well as competitive displacement binding with
10 mM unlabelled CLINDE (CB(CL)), PK11195 (CB(PK)) and PBR111
(CB(PBR)). Speciﬁc binding of [125I]CLINDE is clearly visible in the
Tspo þ / þ mice and is displaceable by all three unlabelled ligands.
Non-speciﬁc binding is seen in areas of nuchal fat or stomach content.

having the same litter size, length of 1-day-old pups, sex ratio,
and subsequent growth rate and weight increase from 3 to 50
weeks (weekly measurement) as the colony control wild-type
Tspo þ / þ animals (Fig. 8a,b). Follow-up monthly measurements
from 50 to 80 weeks failed to reveal any signiﬁcant genotypedependent weight differences in older animals.
Likewise, there was no indication of a decrease in fertility or
lifespan, the oldest animals having so far exceeded 24 months
without illness. Tests of sperm viability and function yielded
no differences between sperm from Tspo þ / þ (mean motility:
82.7±9.33%; mean progress: 47.7±10.2%; mean velocities
average path velocity (VAP): 98.6±13.0 mm s  1, straight line
velocity (VSL): 65.7±8.90 mm s  1 and curvilinear velocity
(VCL): 179±20.2 mm s  1) and Tspo  /  animals (mean motility: 86.1±5.74%; mean progress: 49.6±5.32%; mean velocities
VAP: 105±6.54 mm s  1, VSL: 67.5±5.08 mm s  1 and VCL:
197±11.2 mm s  1). Standard open ﬁeld, emergence, light/dark
preference and elevated plus maze tests revealed similar
behaviour across all genotypes and both sexes (Supplementary
Table 2).
Cholesterol and pregnenolone biosynthesis. In both, male and
female Tspo  /  mice, all serum pregnenolone concentrations,
as measured by enzyme-linked immunosorbent assay (ELISA),
were within the normal range seen in the colony control
wild-type (Tspo þ / þ : males 131±46.5 ng ml  1, females
150±36.5 ng ml  1; Tspo  /  : males 145±44.8 ng ml  1,
females 141±26.8 ng ml  1) (Fig. 8c).
The enzymatic conversion of 3H-cholesterol to pregnenolone
by P450scc over a period of up to 2 h as a read-out of
mitochondrial cholesterol transport revealed no statistically
signiﬁcant differences in mean percentage conversion rates
between all genotypes (Tspo þ / þ : 14.35±4.6% (std); Tspo þ /  :
14.28±3.6% (std); Tspo  /  : 15.6±4.0% (std)).
Haematological analysis and blood biochemistry. Analysis of
blood, including cell sorting, demonstrated that the blood
6

Absence of compensatory transcriptomic regulation. Likewise,
quantitative RT-PCR showed that the gene expression proﬁles for
StAR, P450scc and Tspo2 across the major organs known to
express the Tspo were similar across genotypes, indicating that
the global loss of Tspo had not led to any compensatory
transcriptomic regulation of those genes thought to be most
closely linked to PBR/TSPO as a regulator of steroidogenesis
(Fig. 8e).
Mitochondrial respiration and ATP production in microglia.
Measurements of mitochondrial respiration and ATP production in
primary cultures of mitochondria-rich microglia from Tspo þ / þ
and Tspo  /  mice using the Seahorse XF96 Cell Analyzer and
selective inhibitors of the electron transport chain revealed that
Tspo  /  mitochondria, compared to Tspo þ / þ , have a consistently and signiﬁcantly reduced ATP production as determined
by inhibition of complex V (ATP synthase) with oligomycin (Fig. 9).
Discussion
Orthologues of the PBR, or TSPO, are found widely among
eubacteria, archaea and eukaryotes2,3. Most members of the
PBR/TSPO protein family contain a speciﬁc binding site for the
isoquinoline carboxamide PK11195, which has been used to
pharmacologically deﬁne the PBR/TSPO and distinguish it from
other benzodiazepine-binding receptors, such as the GABAA
receptor protein complex1,3,16. An evolutionarily younger
C-terminal cholesterol recognition amino-acid consensus
(CRAC) domain is primarily found in the animal phylum.
A paralogue of the PBR/TSPO, the TSPO2, exists in birds and
mammals as the result of a gene duplication, which has retained
the CRAC domain but lost the isoquinoline-binding site17.
In light of the evolutionary pressure to conserve the gene, its
documented inﬂuence on steroidogenesis and the previously
observed embryonic lethality caused by the knockout of either the
Tspo5 or the endogenous PBR/TSPO ligand, Acyl-CoA binding
protein18, the survival and overtly normal phenotype of a global
Tspo knockout animal might seem unexpected. However, the
evolutionary preservation of an ancient gene does not necessarily
imply that it is essential, that is, embryonic lethal, nor that an
ancient and non-essential gene is less likely to be relevant for the
emergence of disease. On the contrary, phylostratigraphic analysis
of the human genome suggests that non-essential ancient genes
predominate among the disease-associated genes19. PBR/TSPO
may be considered a non-essential disease gene that lies at the
functional periphery of the interactome with more limited direct
interactions than an in utero essential hub gene20. Consequently,
the functional impact on the Tspo knockout would be predicted
to be discreet.
Our observation that microglia isolated from Tspo knockouts
have altered oxygen consumption and ATP synthesis rates points
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Figure 6 | No inducible TSPO ligand binding in Tspo  /  mice. (a,b) TSPO-binding ligands PK11195 and CLINDE/PBR111. (c) Axotomy of the facial
nerve induces a retrograde neuronal reaction and highly reproducible microglial activation in the injured facial nucleus. (d) Autoradiography with
[3H]PK11195 and [125I]CLINDE and immunohistochemical staining of the microglial activation marker CD11b on consecutive brain sections conﬁrmed the
previously reported localized induction of TSPO ligand binding in the injured facial nucleus contemporaneous to the activation of microglia of Tspo þ / þ
animals. (e) In contrast, no binding of [3H]PK11195 and [125I]CLINDE could be induced in Tspo  /  mice despite the undiminished presence of
activated microglia in the injured facial nucleus, thus providing evidence that the high selectivity of [3H]PK11195 and [125I]CLINDE for their respective
binding sites on the TSPO is retained in pathologically changed tissue. (f) Immunoﬂuorescent anti-CD11b staining of activated microglia in the injured
facial nucleus of Tspo  /  mice revealed no obvious differences in microglial activation, with its characteristic localization of activated, perineuronal
microglia, here (g) shown as higher magniﬁcation of the above section. Scale bars in (d,e) and the left image of (f) denote 1 mm, and that in the right
image of (f) and in (g) 100 mm. The asterixes in (g and f) indicates the soma of neurons.

to a potential latent phenotype that may be elicited under
those disease conditions where a signiﬁcant regulation of the
PBR/TSPO is known to occur13,14. This raises the intriguing
possibility that the disease course notably in inﬂammatory
pathology of the brain, may be different in the absence of the
normally observed, concomitant upregulation of microglial
PBR/TSPO. Immune-modulatory functions of the PBR/TSPO
have previously been suspected based on pharmacological studies
using PBR/TSPO binding compounds that appeared to abrogate
inﬂammatory responses21–23.

Earlier work in bacteria24 suggests other functions than
cholesterol transport for the PBR/TSPO, such as oxygen sensing
and thus co-regulation of mitochondrial ATP production25,
which may become relevant under a range of disease conditions.
Possible functional links of the TSPO to the Fo sub-unit of the
ATP synthase through the VDAC on the outer and ANT on the
inner mitochondrial membrane have been described25,26.
Perceivably, PBR/TSPO-mediated changes in ATP production
might explain indirect regulatory effects on the energy-dependent
steroid biogenesis1,3,10, particularly under stress challenges.
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Figure 7 | PBR/TSPO-expressing brain tumour in global Tspo  /  mouse brain. (a) [18F]PBR111 PET/CT demonstrates a high-contrast signal conﬁned
exclusively to the Tspo þ / þ brain tumour, while Tspo  /  surrounding brain shows no ligand binding. (b,c) For the same animal shown in (a), in vitro
autoradiography with [3H]PK11195 (b) and subsequent immunohistochemical staining with anti-TSPO antibody on the same brain sections (c) conﬁrm that
PBR/TSPO ligand binding is strictly limited to the brain tumour region and no PBR/TSPO binding or recognition sites are present in Tspo  /  tissue.
Scale bars, 1 mm. The PET images show the time frame from 5 to 10 min after injection and scaling is 0–5.3% ID per cm3 for (a).

However, this alternative explanation of a functional association
of the PBR/TSPO with steroid biogenesis necessitates reexamination of a substantial body of published research to
separate direct from indirect or from non-selective, off-target
effects. Many studies use compounds with purported selectivity
for the PBR/TSPO for diagnostic or therapeutic purposes, such as
those modulating complex behaviour in the apparent absence of
binding to neural receptor systems7. Our study paradigmatically
demonstrated for a long-established as well as a recently
developed PBR/TSPO compound, that is, PK11195 and
CLINDE/PBR111, respectively, that the Guwiyang Wurra
Tspo  /  strain is a powerful tool to discern selective from
non-selective off-target binding and thus validate the purported
drug actions in live animals under naturalistic conditions. We
also anticipate innovative lipid membrane studies into the
biophysical mechanisms by which ligands for the PBR/TSPO
may either modify or introduce additional, potentially nonreceptor, actions in the presence or absence of the protein1,27,28.
Lastly, the apparent irrelevance of the PBR/TSPO for the
normal activation of microglia after neuronal injury indicates that
neuro-glial interactions and inﬂammatory tissue responses are
separate processes, though in vivo neuroimaging studies on both
may regularly show high levels of PBR/TSPO expression13,14. The
current concepts of ‘neuroinﬂammation’ do not adequately
distinguish these and, therefore, too, merit revisiting.
The extensively characterized Guwiyang Wurra Tspo  / 
strain provides the broader research community with a means
of dissecting the network of pathways through which the
PBR/TSPO exerts its regulatory inﬂuence at the intersection
of cell metabolism, innate immune response and endocrine
regulation of behaviour in health and disease.
Methods

Generation of Tspo  /  mice. Tspo knockout mice were generated using a targeting construct that contained loxP sites ﬂanking exons 2 and 3, and a neomycin
cassette inserted between exons 3 and 4. The targeting construct was electroporated
8

into C57BL/6 Bruce4 embryonic stem (ES) cells and cells correctly targeted by
homologous recombination were injected into albino C57BL/6 blastocysts. Male
chimeras were mated to female albino C57BL/6 mice and the resulting offspring
with a black coat were screened for the presence of a targeted Tspo allele.
Mice positive for the presence of the targeted allele were crossed with C57BL/6
Cre deleter mice to remove the neomycin cassette and exons 2 and 3 to create
heterozygous global Tspo deﬁcient mice. To remove the Cre transgene, animals
were bred to wild-type C57BL/6 mice.
To produce animals for experiments, heterozygous mice were crossed to
generate wild-type littermate controls. All animal procedures were approved by the
University of Sydney Animal Ethics Committee and the ANSTO Animal Care and
Ethics Committee. The Tspo  /  mouse strain has been given the additional
designation Guwiyang Wurra (‘ﬁre mouse’ in the local Dharawal language). Future
naming will thus be C57BL/6-Tspotm1GuMu(GuwiyangWurra).
Mice were genotyped by Southern blot analysis using genomic DNA isolated
from tail biopsies. For routine genotyping, genomic DNA was isolated from tail
biopsies, ear biopsies or stool samples and ampliﬁed by PCR to generate a 489-bp
product for the wild-type allele and a 246-bp product for the knockout allele. See
Supplementary Table 4 for primer sequences. The PCR consisted of an initial
incubation at 95 °C for 2 min, followed by 4 cycles at 95 °C for 30 s, 68 °C for 30 s
and 72 °C for 2 min, then 4 cycles at 95 °C for 30 s, 65 °C for 30 s and 72 °C for
2 min, then 30 cycles at 95 °C for 30 s, 62 °C for 30 s and 72 °C for 2 min, and a ﬁnal
step at 72 °C for 5 min.
Immunoblotting. Lysates (20 mg protein) were mixed with 2  Laemmli sample
buffer (Bio-Rad, Hercules, CA, USA), heated to 70 °C for 10 min and resolved on a
4–20% Mini-PROTEAN TGX gel (Bio-Rad). MagicMark XP (Life Technologies,
Carlsbad, CA, USA) was used as the molecular weight marker. Proteins were
transferred to a nitrocellulose membrane using the Trans-Blot Turbo transfer
system (Bio-Rad). The membrane was incubated with anti-TSPO antibody
(#109497, Abcam, Cambridge, UK) diluted 1:10,000 or anti-GAPDH (#37168,
Abcam) diluted 1:1,000 and peroxidase-conjugated anti-rabbit antibody (#A0545,
Sigma-Aldrich, St Louis, MO, USA) diluted 1:10,000. Pierce ECL Western Blotting
Substrate (Thermo Scientiﬁc, Rockford, IL, USA) was used and the membrane
visualized using an ImageQuant LAS 4000 (GE Healthcare, Little Chalfont,
Buckinghamshire, UK).
RT-PCR and quantitative real-time PCR. Tissue samples were homogenised in
TRIzol (Life Technologies) and total RNA isolated using the PureLink RNA mini
kit (Life Technologies) with on-column DNase treatment following the manufacturer’s instructions. Puriﬁed RNA (1 mg) was reverse-transcribed to cDNA using
the SuperScript III First-Strand Synthesis kit (Life Technologies). For RT-PCR,
cDNA from the kidneys of Tspo þ / þ and Tspo  /  mice was ampliﬁed using

NATURE COMMUNICATIONS | 5:5452 | DOI: 10.1038/ncomms6452 | www.nature.com/naturecommunications

& 2014 Macmillan Publishers Limited. All rights reserved.

ARTICLE

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6452

a

b
50

20
10
0

Male

Female

40

30
Weight (g)

Body length (mm)

40

30
20

Tspo+/+
Tspo+/–
Tspo–/–

10
0

–/–
Tspo+/+ Tspo

0

10

20

30

40

50 0

10

20

30

40

50

Time (weeks)

c

d
Pregnenolone
Fluorescence (A.U.
per ml)

Pregnenolone
(ng per ml)

250
200
150
100
Tspo+/+
Tspo–/–

50
0
Male

1,500

1500

Tspo+/+
Tspo+/–

1,000

1000

Tspo–/–

500

500

PPIX

0

0
450

Female

(–) ALA

550
650
750
Wavelength (nm)

(+) ALA

Liver

Heart

Kidney

Eyes

Brain

Lung

Testes

Tspo 2

Spleen

Liver

Heart

Kidney

Eyes

Brain

Lung

Liver

Kidney

Heart

Eyes

Brain

0.01
Lung

0.01
Testes

1
0.1
Testes

1
Tspo+/+
–/–0.1
Tspo
0.01

1

Spleen

10

0.1
Spleen

100

P450scc

10

Adrenal

100

StAR

10

Adrenal

100

Adrenal

Normalized mRNA
expression

e

Figure 8 | Functional characterization of global Tspo  /  mice. (a) No signiﬁcant differences in body length between Tspo þ / þ (n ¼ 5) and Tspo  / 
(n ¼ 9) neonatal 1-day-old mice are apparent (Student’s t-test). (b) Likewise, there is no signiﬁcant difference (ANOVA) in the weight gain trajectory
measured from 4 to 83 weeks in Tspo þ / þ , Tspo þ /  and Tspo  /  mice within the same sex (n ¼ 10–80 animals per time point for weeks 4–43 per group;
n ¼ 3–44 per time point for weeks 44–83). Independent from genotypes, females weigh signiﬁcantly less than males, as is known to be the case for
this mouse strain (b). (c–e) No signiﬁcant differences between Tspo þ / þ and Tspo  /  mice are found in blood pregnenolone concentrations (n ¼ 4 for
all groups; Student’s t-test) (c); blood protoporphyrin IX (PPIX; left: three typical closely overlapping spectra from the different genotypes after addition
of 5-aminolevulinic acid (ALA), right: no signiﬁcant differences in levels of PPIX (PPIX per ml of blood in arbitrary units (A.U.); n ¼ 3–5 per genotype;
Student’s t-test)) (d); and mRNA expression of steroidogenic acute regulatory (StAR) protein, P450scc and Tspo2 in nine organs (normalized to
reference genes Actb and Gapdh, n ¼ 3 per genotype) (e). Error bars denote standard deviation.
primers (Supplementary Table 4) located in exons 1 and 4. The PCR consisted of
an initial incubation at 95 °C for 2 min, followed by 34 cycles at 95 °C for 30 s,
55 °C for 30 s and 72 °C for 1 min, and a ﬁnal step at 72 °C for 5 min. The PCR
products were conﬁrmed by sequencing. For quantitative real-time PCR, cDNA
was added to 2.5 ml of SsoFast EvaGreen Supermix (Bio-Rad) and 0.5 mM of each
primer (Supplementary Table 4) in a ﬁnal reaction volume of 5 ml. Reactions were
performed on a CFX 384 Real-Time PCR detection System (Bio-Rad) by cycling at
98 °C for 30 s, followed by 45 cycles at 98 °C for 5 s and 63 °C (61 °C for the Tspo2
assay) for 10 s. A melt curve analysis was performed to conﬁrm the speciﬁcity of
each reaction. Each sample was run in duplicate. The Tspo2 primers were designed
using Primer-BLAST and the speciﬁcity conﬁrmed by DNA sequencing.
Protoporphyrin IX. Blood from euthanized mice was placed into heparin tubes on
ice, plasma removed, cells washed twice in ice-cold phosphate-buffered saline
(PBS) and then resuspended in PBS to the original volume. Samples were evenly
split (300 ml each), one receiving 1 mM 5-ALA and the other sterile H2O, and
incubated in a shaking incubator at 37 °C for 4 h. Ethyl acetate/acetic acid (4:1) was
added to each sample, then mixed and centrifuged before transferring the supernatant (1 ml) to a new tube with 1 ml of 1.5 M HCl. An aliquot of the lower HCl
phase, after mixing and centrifuging the sample, was measured in a spectroﬂuorimeter (excitation wavelength 407 nm, slit width 10 nm, emission spectrum
450–800 in 1 nm increments). Glass tubes and containers were used throughout
and samples were protected from light.
Facial nerve axotomy. Facial nerve axotomy29,30 was performed on Tspo þ / þ and
Tspo  /  mice (n44 per genotype) anaesthetized with 5% (v/v) isoﬂurane.

A small incision (0.5–0.7 cm) in the skin 0.5 cm dorsal and lateral to the ear was
made and the facial nerve transected under an operating microscope. The incision
was closed with Vetbond Tissue Adhesive (3M, St Paul, MN, USA). The success of
the operation was conﬁrmed by the loss of ipsilateral whisker movement. Mice
were monitored carefully and euthanized with CO2 3 days after the operation.
Brains were dissected, placed in OCT, transferred to liquid nitrogen and stored
at  80 °C until cryo-sectioning.
Stereotactic implantation of GL261 mouse glioblastoma cells. The Tspo þ / þ
(n ¼ 6) and Tspo  /  mice (n ¼ 4) were operated under isoﬂuorane anaesthesia
and aseptic conditions using a Kopf stereotactic apparatus and precision dental
drill (Kopf Instruments, Tujunga, CA, USA). A small burr hole was made 3 mm
anterior of the bregma and 2 mm lateral over the right frontal lobe (3 mm ventral).
GL261 glioblastoma cells (NCI, Bethesda, MD, USA) at 3  103 per ml in a volume
of 10 ml were slowly injected over 2 min using a 10-ml Hamilton syringe connected
to a pump by means of a 32-gauge needle. The animals were closely monitored
daily for good recovery, including body weight and absence of neurological signs.
Three and four weeks after implantation of the GL261 cells, the animals were
imaged by means of microPET/CT and brains were dissected for histological
studies and autoradiography.
PET and CT imaging. Mice, anaesthetized (5% (v/v) with isoﬂurane and maintained at 1–2%, were scanned using a small-animal Inveon PET/CT scanner
(Siemens, Knoxville, TN, USA) according to the methods described previously31,32.
Body temperature was maintained with a feedback regulated heating pad and
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Figure 9 | Decreased metabolic activity in Tspo  /  microglia. (a–c) The basal, that is, mitochondrial and non-mitochondrial, oxygen consumption
rate (OCR) is consistently and signiﬁcantly lower in Tspo  /  microglia compared to Tspo þ / þ microglia (Tspo  /  : 49.0±16.3 pmol per min; n ¼ 95;
Tspo þ / þ : 81.0±21.8 pmol per min, n ¼ 154; Student’s t-test), while OCR after application of the ATPase inhibitor oligomycin (3 mM) is reduced to similar
levels in both genotypes (n ¼ 11–14 per group) (a). Thus, the oligomycin-inhibitable mitochondrial ATP production in Tspo  /  microglia is signiﬁcantly
lower than in Tspo þ / þ microglia (*Po0.01; Student’s t-test) (c). Basal mitochondrial OCRs in Tspo  /  and Tspo þ / þ microglia after inhibition of the
electron transport chain complexes I and III with 10 mM rotenone þ 10 mM antimycin A are reduced by similar amounts (c) and to similar levels
(b) (n ¼ 11–14 per group). (d) Metabolic activity is decreased in Tspo  /  microglia. Basal OCR vs ECAR (extracellular acidiﬁcation rate) shows that both
OCR and ECAR in Tspo  /  microglia (n ¼ 95) are lower than those in Tspo þ / þ microglia (n ¼ 154). Error bars denote standard deviation for (a–d).
Further extensive hematological and behavioural data are presented in Supplementary Tables 2 and 3.
respiration monitored (BioVet; m2m Imaging Corp, Cleveland, OH, USA). Scans
started with the tail vein injection of [18F]PBR111 (8–18 MBq per 100 ml, 0.2 nM).
After 40 min of imaging, PBR111 (1 mg per kg in 2% acetic acid–saline) was
injected to determine non-speciﬁc accumulation in organs and imaged for 10 min.
Then, mice underwent a 10-min CT scan for anatomical information. All PET data
were corrected, normalized and reconstructed with an OSEM3D–MAP algorithm31
to produce PET volumes of activity concentration (kBq per ml).
Autoradiography. Tissue sections from Tspo þ / þ , Tspo þ /  and Tspo  /  mice
were incubated at room temperature for 20 min in 170 mM Tris-HCl pH 7.4
containing 1 nM [3H]PK11195 (speciﬁc activity 84 Ci per mmol; Perkin Elmer,
Waltham, MA, USA), washed twice for 5 min in 170 mM Tris-HCl, rinsed with
3 dips in ice-cold MilliQ H2O, and dried. Additional sections were incubated on ice
for 1 h in 50 mM Tris-HCl pH 7.4 containing 3 nM [125I]CLINDE (speciﬁc activity
100 Ci per mmol; synthesized by ANSTO Life Sciences), washed twice for 2 min in
ice-cold 50 mM Tris-HCl, for 1 min in ice-cold MilliQ H2O, and dried. Displacement binding was carried out in the presence of PK11195 (10 mM), CLINDE
(10 mM) and PBR111 (10 mM). Single-emulsion ﬁlms were exposed to sections and
standards (14C or 3H) for 3 h ([125I]CLINDE) or 10 weeks ([3H]PK11195).
Immunohisto- and cytochemistry. Immunohistochemistry was performed as
previously described13,33,34. Tissue sections (used for autoradiography) were ﬁxed
with 3.7% formaldehyde in PBS for 5 min, then permeabilized with ice-cold
acetone. Non-speciﬁc antibody binding was blocked with 10% horse serum and 2%
bovine serum albumin (BSA) in PBS. Sections were incubated with TSPO
monoclonal antibody (#109497, Abcam) at 4 °C overnight and secondary
HRP-conjugated goat anti-rabbit antibody at RT for 1 h (#A0545, Sigma-Aldrich).
The activity of HRP was detected with the peroxidase 3,30 -diaminobenzidine
tetrahydrochloride liquid substrate system (Sigma-Aldrich). Sections were
dehydrated with ethanol, incubated with xylene, and slides were mounted in DPX
10

mounting media with a coverslip. Sections were visualized under an inverted
Olympus BX51 microscope (Olympus, Tokyo, Japan), and captured with a
Q-imaging camera and ImagePro 5.1 program.
A Zeiss LSM 710 confocal microscope with a 5  EC Plan-Neoﬂuar NA 0.16
objective was used for the ﬂuorescence microscopy of the facial nucleus. Alexa
Fluor 568 was excited with a 561-nm laser, using a 488/561/633 dichroic mirror,
and emission captured from 565 to 640 nm.
For immunocytochemistry, peritoneal macrophages were isolated according to
Zhang et al.35. After 2 days in complete cultural medium the purity of macrophages
was 497% as conﬁrmed with the macrophage-speciﬁc marker IB4 conjugated with
FITC (Sigma-Aldrich). Cells on coverslips were ﬁxed and incubated using the same
method as for tissue sections, with the addition of a mouse anti-human/mouse
mitochondrial electron transport chain complex IV antibody (#AB14705, Abcam),
then incubated with the secondary antibodies Alexa Fluor (AF) 594-conjugated
goat anti-rabbit antibody (Life Technologies) and AF488-conjugated goat antimouse antibody (Life Technologies). Cells on coverslips were mounted on
microscope slides with ProLong Gold antifade reagent containing DAPI (Life
Technologies) and viewed under a BX61WI Olympus microscope. Images were
acquired with a digital camera (CoolSNAP, Photometrics, Tucson, AZ, USA) and
the Image InVivo program (Photometrics). Deconvolution of images was
performed with the AutoDeblur program (Photometrics) and further processed
with ImageJ (NIH, Baltimore, MD, USA).

Primary microglial cell culture. Microglia were cultured from 0–2-day-old
Tspo þ / þ and Tspo  /  mice according to methods described previously33. Brieﬂy,
whole brains were dissected, cut into ﬁne pieces and treated with 0.025% trypsin
(Sigma-Aldrich). They were cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM/F12; Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS;
Life Technologies), 1% penicillin-streptomycin-glutamine (Sigma-Aldrich) and
0.5 ng per ml GM-CSF (Abcam).
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Microglia were puriﬁed by shaking at 350 revolutions per minute (r.p.m.) for
50 min at 37 °C, pelleted by centrifugation, resuspended in supplemented DMEM/
F12 and placed (4  104 cells per well) into a 96 well Seahorse XF cell culture plate
(Seahorse Bioscience, North Billerica, MA, USA) pre-coated with FBS for 15 min at
room temperature. After 15 min the wells were washed twice to remove unattached
cells. The purity of microglial cultures was 498% as conﬁrmed by staining with the
microglial marker Alexa Fluor-conjugated isolectin GS-IB4 (Life Technologies).
The 5  104 microglia from wild-type and knockout mice were plated into
each well of the XF96 plate and were grown for 2–3 days before evaluating
mitochondrial functions with the Seahorse XF 96 Cell Analyzer (Seahorse
Bioscience). To rule out systematic differences in cell density and viability between
Tspo þ / þ and Tspo  /  microglia, cell density was monitored and assured
throughout the experimental measurements, while viability, including apoptosis,
was conﬁrmed using caspase 3/7 (ref. 36).
Measurements of mitochondrial respiration. The oxygen consumption rate
(OCR) and extracellular acidiﬁcation rate in primary microglial cultures were
determined using the Seahorse XF 96 Cell Analyzer. OCR is an indicator of
mitochondrial respiration37,38. The day before the experiment 200 ml of the
Seahorse XF Calibrant (pH 7.4) was added to each well of the XF 96-well utility
plates. The sensor cartridge was placed on top of the plate and hydrated for 16 h at
37 °C in a non-CO2 incubator. The protocol for basal measurements of the cells at
37 °C (start, calibrate probes, equilibrate, mix 2 min, 1 min delay, measure 3 min)
was repeated twice. Mitochondrial stress compounds (oligomycin, rotenone
combined with antimycin A) were then injected, followed by 2 min mixing, 1 min
delay, measure 3 min (repeated 3 times).
On the day of the experiment, microglia (plating density 5  105 per well, purity
498% and viability 492% for both wild-type and knockout microglia) were
washed 3 times with un-buffered DMEM plus 20 mM glucose (no buffers) and
incubated at 37 °C (no CO2) for 1 h. Oligomycin and rotenone combined with
antimycin A were used to determine mitochondrial ATP production and basal
mitochondrial OCR37,38. Oligomycin and the combination of rotenone and
antimycin A were injected at concentrations of 0.3, 1 and 3 mM (optimal for
oligomycin) and 10 mM (optimal for rotenone and antimycin A).
The data for each reported parameter reﬂect 11–14 independent Seahorse XF
measurement series from a total of seven independently repeated microglial cell
culture preparations.
Radioligand binding. Organs were homogenized using a T25 digital Ultra-Turrax
homogenizer (Ika, Wilmington, NC, USA) at speed setting 5 and 20,000 r.p.m. in
B45 ml of ice-cold TRIS buffer (pH 7.4) and washed twice in ice-cold 50 mM
Tris-HCl (pH 7.4) by centrifugation at 48,000 g, resuspended in 50 volumes of
ice-cold 50 mM Tris-HCl, and protein concentration was determined using a BCA
protein assay kit (Thermo Scientiﬁc). Bmax and Kd were determined with
saturation binding by incubating membrane protein (60 ml) with [3H]PK11195
(0.56–20 nM) on ice for 90 min before harvesting by rapid ﬁltration through
Whatman GF/C ﬁlters (GE Healthcare) presoaked in a 0.5% polyethylenimine
solution. Non-speciﬁc binding was determined with 5 mM PK11195. Filters were
placed in scintillation cocktail (Perkin Elmer) for 12 h and radioactivity was
determined using a Tri-Carb 2100 TR Liquid Scintillation Counter (Perkin Elmer).
Bmax and Kd values were obtained by non-linear regression using GraphPad
Prism 5.04 (GraphPad Software, La Jolla, CA, USA) by ﬁtting total and nonspeciﬁc binding.
Cholesterol transport and biosynthesis. P450scc metabolism was measured in
mouse testis according to Tuckey et al.39 and Slominski et al.40. Brieﬂy, an enriched
mitochondrial fraction was prepared by centrifugation in 250 mM sucrose, 50 mM
Tris (pH 7.4), and the enzymatic conversion of cholesterol to pregnenolone was
conducted under the following conditions out to a maximum 2-h time-point:
50 mM HEPES pH 7.4, 250 mM sucrose, 20 mM KCl, 5 mM MgSO4, 0.2 mM
EDTA, 1 mg per ml BSA, 8 mM Trilostane, 0.05 mCi 3H-cholesterol, 500 mM
isocitrate and 5 mM NaNADP. Reactions were terminated with the addition of 4 °C
dichloromethane. The organic phase was retained and the aqueous phase was
re-extracted twice more into dichloromethane. Extracts were combined, dried
under nitrogen and dissolved in 100 ml of ethyl acetate. Pregnenolone and
cholesterol were separated by thin-layer chromatography, with
hexane:diethylether:acetic acid (15:15:1) mobile phase, and the amount of
radioactivity in each spot quantiﬁed by liquid scintillation counting.
Detection of serum pregnenolone. Serum pregnenolone of male and female
Tspo þ / þ and Tspo þ / þ mice was determined by ELISA performed according to
the manufacturer’s instructions (Abnova Cooperation, Taiwan). Brieﬂy, blood was
collected, allowed to clot, and the serum collected. Standards, controls and samples
were incubated in duplicate in a sealed plate with or without conjugate and antibody for 1 h at room temperature on a plate shaker (KS4000ic, IKA, Selangor,
Malaysia) at 200 r.p.m. After the incubation, wells were emptied, washed ﬁve times,
and the plate tapped on lint free paper towel to remove any remaining buffer. Wells
were incubated with HRP conjugate on the plate shaker at 200 r.p.m. for 30 min at
room temperature, washed ﬁve times, and incubated with TMB substrate for

10 min at room temperature. Stop solution was added to each well and after 20 min
the optical density at 450 nm was measured. Data were normalized against blood
volume and analysed using a four-parameter logistic curve ﬁtting program
MasterPlex ReaderFit: Curve-Fitting Software for ELISA Analysis (Hitachi
Solution America, San Francisco, CA, USA).
Blood phenotyping. Thirty mice (10 Tspo þ / þ , 10 Tspo þ /  , 10 Tspo  /  ,
5 months old, males/females evenly distributed) used in behavioural experiments
were euthanized with CO2. Blood was collected from the pulmonary cavity by
cutting the inferior vena cava and placed in microtubes with heparin (haematology
and lymphocyte analysis) or gel clot activator (biochemical analysis). Spleens were
collected in 10 ml of ice-cold sterile PBS. Blood (room temperature) and spleens
(on ice) were delivered (within 3–7 h of collection) to the Australian Phenomics
Facility for ﬂow cytometric and biochemical analysis.
For general haematology, blood was diluted 1:2 and analysed with ﬂuorescenceactivated cell sorting using the Advia 2120 Haematology System (Siemens, Munich,
Germany). Blood cell subsets, including white blood cells and platelets, were
assessed. For lymphocyte analysis, blood was analysed for the presence or absence
of abnormalities in T cells, B cells, NK cells and monocytes. The T-cell subsets
included CD4 þ and CD8 þ subsets, while the B-cell subsets included immature
and mature B cells and IgE þ monocytes. Spleens were analysed by ﬂow cytometry
and stained for NK cells, for B cells, including mature and immature subsets, and
for T cells, including CD4 þ and CD8 þ cells and their activated subsets. See
Supplementary Table 3 for a list of cell types examined.
For biochemistry, blood was centrifuged, the serum collected and run through
the Olympus AU400 Chemistry Analyzer (Olympus), which detects levels of
cholesterol, triglycerides, glucose, high-density lipoprotein (HDL), albumin,
creatine kinase activity and alanine aminotransferase activity. See Supplementary
Table 3 for a list of biochemical parameters examined.
Mouse sperm analysis. Sperm were released from the cauda epididymides of
Tspo þ / þ and Tspo  /  mice by cutting each cauda with a scalpel and incubating
in 150 ml of pre-warmed Biggers–Whitten–Whittingham (BWW) medium for
5 min at 37 °C. After the incubation, an additional 250 ml of BWW medium was
added, the tissue removed and the sperm assessed using a computer-assisted sperm
analysis system (Hamilton Thorne, Beverly, MA, USA). Parameters assessed were
total motile, progressive motile, VAP, VSL and VCL.
Assessment of anxiety-related behaviours. Behavioural tests were performed on
mice aged between 3–4 months, handled regularly to reduce the impact of handling
stress during testing. Anxiety-related behaviours were examined with the following:
open-ﬁeld test, emergence test, light/dark preference test and elevated plus maze. In
each test the mice were allowed free exploration in the apparatus for 15 min. The
duration and frequency of entering each compartment, total distance travelled,
time spent active and the number of stool droppings were assessed. In the elevated
plus maze risk assessment was deﬁned as when an animal’s head was facing
towards an open arm with more than 15% of its body in an open arm while
maintaining its centre of mass within the closed arm or central platform. The
genotype of the animals was blind to the experimenter during testing. Tests were
carried out at least 7 days apart to reduce the effects of training history41. All
experiments were recorded with an overhead camera on to DVD and later analysed
using Motman Tracker 4.5 software (Motion Mensura, Cooks Hill, NSW,
Australia).
Data analysis. Statistical signiﬁcance was calculated using an unpaired two-tailed
Student’s t-test for two-group comparisons. For comparisons of more than two
groups univariate analysis of variance (ANOVA) with a Bonferroni’s post-hoc test
was performed and considered signiﬁcant at Po0.05. Data are presented as
mean±standard deviation, except where indicated otherwise.
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